187 related articles for article (PubMed ID: 29562656)
1. Evaluation of Promoter Methylation of RASSF1A and ATM in Peripheral Blood of Breast Cancer Patients and Healthy Control Individuals.
Cao X; Tang Q; Holland-Letz T; Gündert M; Cuk K; Schott S; Heil J; Golatta M; Sohn C; Schneeweiss A; Burwinkel B
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562656
[TBL] [Abstract][Full Text] [Related]
2. Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer.
Papadopoulou E; Davilas E; Sotiriou V; Georgakopoulos E; Georgakopoulou S; Koliopanos A; Aggelakis F; Dardoufas K; Agnanti NJ; Karydas I; Nasioulas G
Ann N Y Acad Sci; 2006 Sep; 1075():235-43. PubMed ID: 17108217
[TBL] [Abstract][Full Text] [Related]
3. Promoter Methylation of BRCA1, DAPK1 and RASSF1A is Associated with Increased Mortality among Indian Women with Breast Cancer.
Yadav P; Masroor M; Nandi K; Kaza RCM; Jain SK; Khurana N; Saxena A
Asian Pac J Cancer Prev; 2018 Feb; 19(2):443-448. PubMed ID: 29480000
[TBL] [Abstract][Full Text] [Related]
4. Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening.
Kloten V; Becker B; Winner K; Schrauder MG; Fasching PA; Anzeneder T; Veeck J; Hartmann A; Knüchel R; Dahl E
Breast Cancer Res; 2013 Jan; 15(1):R4. PubMed ID: 23320751
[TBL] [Abstract][Full Text] [Related]
5. Aberrant methylation of RASSF1A in plasma DNA before breast cancer diagnosis in the Breast Cancer Family Registry.
Yazici H; Terry MB; Cho YH; Senie RT; Liao Y; Andrulis I; Santella RM
Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2723-5. PubMed ID: 19755643
[TBL] [Abstract][Full Text] [Related]
6.
Karamat U; Ejaz S; Hameed Y
Genet Test Mol Biomarkers; 2021 Apr; 25(4):263-275. PubMed ID: 33877897
[No Abstract] [Full Text] [Related]
7. Blood-based DNA methylation as biomarker for breast cancer: a systematic review.
Tang Q; Cheng J; Cao X; Surowy H; Burwinkel B
Clin Epigenetics; 2016; 8():115. PubMed ID: 27895805
[TBL] [Abstract][Full Text] [Related]
8. Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay.
Yamamoto N; Nakayama T; Kajita M; Miyake T; Iwamoto T; Kim SJ; Sakai A; Ishihara H; Tamaki Y; Noguchi S
Breast Cancer Res Treat; 2012 Feb; 132(1):165-73. PubMed ID: 21594664
[TBL] [Abstract][Full Text] [Related]
9. Impact of RASSF1A gene methylation on clinico-pathological features of tumor and non-tumor tissue of breast cancer.
Gupta V; Agarwal P; Deshpande P
Ann Diagn Pathol; 2021 Jun; 52():151722. PubMed ID: 33621744
[TBL] [Abstract][Full Text] [Related]
10. Detection and monitoring of hypermethylated RASSF1A in serum from patients with metastatic breast cancer.
Kristiansen S; Nielsen D; Sölétormos G
Clin Epigenetics; 2016; 8():35. PubMed ID: 27042241
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation patterns of RAR-β2 and RASSF1A gene promoters in FNAB samples from Greek population with benign or malignant breast lesions.
Kougioumtsidou N; Vavoulidis E; Nasioutziki M; Symeonidou M; Pratilas GC; Mareti E; Petousis S; Chatzikyriakidou A; Grimbizis G; Theodoridis T; Miliaras D; Dinas K; Zepiridis L
Diagn Cytopathol; 2021 Jan; 49(1):153-164. PubMed ID: 32530576
[TBL] [Abstract][Full Text] [Related]
12. Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk.
Brennan K; Garcia-Closas M; Orr N; Fletcher O; Jones M; Ashworth A; Swerdlow A; Thorne H; ; Riboli E; Vineis P; Dorronsoro M; Clavel-Chapelon F; Panico S; Onland-Moret NC; Trichopoulos D; Kaaks R; Khaw KT; Brown R; Flanagan JM
Cancer Res; 2012 May; 72(9):2304-13. PubMed ID: 22374981
[TBL] [Abstract][Full Text] [Related]
13. Linking ATM Promoter Methylation to Cell Cycle Protein Expression in Brain Tumor Patients: Cellular Molecular Triangle Correlation in ATM Territory.
Mehdipour P; Karami F; Javan F; Mehrazin M
Mol Neurobiol; 2015 Aug; 52(1):293-302. PubMed ID: 25159481
[TBL] [Abstract][Full Text] [Related]
14. Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer.
Spitzwieser M; Holzweber E; Pfeiler G; Hacker S; Cichna-Markl M
Breast Cancer Res; 2015 Sep; 17(1):125. PubMed ID: 26370119
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA.
Ahmed IA; Pusch CM; Hamed T; Rashad H; Idris A; El-Fadle AA; Blin N
Cancer Genet Cytogenet; 2010 Jun; 199(2):96-100. PubMed ID: 20471512
[TBL] [Abstract][Full Text] [Related]
16. RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer.
Sebova K; Zmetakova I; Bella V; Kajo K; Stankovicova I; Kajabova V; Krivulcik T; Lasabova Z; Tomka M; Galbavy S; Fridrichova I
Cancer Biomark; 2011-2012; 10(1):13-26. PubMed ID: 22297548
[TBL] [Abstract][Full Text] [Related]
17. Association Between
Markulin D; Vojta A; Samaržija I; Gamulin M; Bečeheli I; Jukić I; Maglov Č; Zoldoš V; Fučić A
Cancer Genomics Proteomics; 2017; 14(5):363-372. PubMed ID: 28871003
[TBL] [Abstract][Full Text] [Related]
18. Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients.
Flanagan JM; Munoz-Alegre M; Henderson S; Tang T; Sun P; Johnson N; Fletcher O; Dos Santos Silva I; Peto J; Boshoff C; Narod S; Petronis A
Hum Mol Genet; 2009 Apr; 18(7):1332-42. PubMed ID: 19153073
[TBL] [Abstract][Full Text] [Related]
19. Different methylation and microRNA expression pattern in male and female familial breast cancer.
Pinto R; Pilato B; Ottini L; Lambo R; Simone G; Paradiso A; Tommasi S
J Cell Physiol; 2013 Jun; 228(6):1264-9. PubMed ID: 23160909
[TBL] [Abstract][Full Text] [Related]
20. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
